Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silo Pharma (SILO) Gains from Investment Securities (2019 - 2025)

Silo Pharma's Gains from Investment Securities history spans 5 years, with the latest figure at $989.0 for Q2 2025.

  • For Q2 2025, Gains from Investment Securities rose 178.55% year-over-year to $989.0; the TTM value through Sep 2025 reached $3911.0, up 222.07%, while the annual FY2024 figure was $22850.0, N/A changed from the prior year.
  • Gains from Investment Securities for Q2 2025 was $989.0 at Silo Pharma, down from $2922.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $22850.0 in Q4 2024 and bottomed at -$129859.0 in Q4 2022.
  • The 4-year median for Gains from Investment Securities is $234.0 (2024), against an average of -$15186.0.
  • The largest annual shift saw Gains from Investment Securities surged 42.22% in 2024 before it skyrocketed 1148.72% in 2025.
  • A 4-year view of Gains from Investment Securities shows it stood at -$129859.0 in 2022, then skyrocketed by 98.32% to -$2179.0 in 2023, then skyrocketed by 1148.65% to $22850.0 in 2024, then crashed by 95.67% to $989.0 in 2025.
  • Per Business Quant, the three most recent readings for SILO's Gains from Investment Securities are $989.0 (Q2 2025), $2922.0 (Q1 2025), and $22850.0 (Q4 2024).